Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.
Although infection with cytomegalovirus (CMV) continue to be recognized relatively frequently after organ transplantation, a decrease in their severity has been described with the use of newer immunosuppressive regimens. In particular whereas antithymocyte globulin was associated with an increase in morbidity and mortality, the use of cyclosporin A has resulted in a decrease in the frequency of symptomatic infections. Several sources of CMV infection in transplant recipients are: immunosuppression secondary to drug therapy can result in reactivation of the latent infection present before transplantation; blood transfusion, either pretransplant red blood cell transfusion or blood required at the time of surgery can also result in transmission of CMV and primary infection; the transplanted kidney or heart, particularly in situations in which seropositive organs are transmitted into seronegatives can serve as the vehicle for transmission. Recent data suggest that transmission of organ donor CMV can occur even in seropositive recipients. The clinical manifestations of CMV infection in transplant recipients range from asymptomatic or mild mononucleosis syndromes to severe infection. It is generally accepted that primary infections in patients who were seronegative before transplantation are more severe than reactivated infections. Involvement of multiple organ systems has been common, with retinitis, pneumonitis and gastrointestinal manifestations occurring most commonly. A specific CMV infection of the kidney has also been described but its manifestations are variable. The association of CMV infections with rejection remains controversial in human transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
Pollard
R B
RB
Department of Internal Medicine and Microbiology, University of Texas Medical Branch, Galveston 77550.
D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D015774:Ganciclovir; D016027:Heart Transplantation; D016041:Heart-Lung Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007372:Interferons / Q000627:therapeutic use; D016030:Kidney Transplantation; D016031:Liver Transplantation; D016040:Lung Transplantation; D011183:Postoperative Complications / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D012008:Recurrence; D014611:Vaccination
D000998:Antiviral Agents; D007372:Interferons; D015774:Ganciclovir; D000212:Acyclovir